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orepinephrine Transporter
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hristoph Schroeder, MD,* Andreas L. Birkenfeld, MD,* Antje F. Mayer,* Jens Tank, MD,*
ndre Diedrich, MD, PHD,† Friedrich C. Luft, MD,* Jens Jordan, MD*
erlin, Germany; and Nashville, Tennessee
OBJECTIVES We tested the hypothesis that pharmacological norepinephrine reuptake transporter (NET)
inhibition delays the onset of head-up tilt-induced presyncope in healthy subjects.
BACKGROUND Treatment of neurally mediated syncope is unsatisfactory. In a previous study in a small
number of healthy subjects, pharmacologic NET inhibition delayed the onset of head-up
tilt-induced pre-syncope.
METHODS We combined data sets from 3 substudies comprising 51 healthy subjects without a history of
syncope. In a double-blind, randomized, cross-over fashion, subjects underwent 2 head-up tilt
tests, once with placebo and once with a NET inhibitor (sibutramine or reboxetine). Tilt
testing was prematurely ended when pre-syncopal symptoms such as dizziness, nausea, or
visual disturbances occurred together with a decrease in blood pressure and/or heart rate.
RESULTS The mean tolerated tilt test duration was 29 2 min with placebo and 35 1 min with NET
inhibition (p 0.001). The odds ratio for premature abortion of head-up tilt testing was 0.22
(95% confidence interval 0.09 to 0.55, p  0.001) in favor of NET inhibition. Norepineph-
rine reuptake transporter inhibition elicited a pressor response and increased upright heart
rate.
CONCLUSIONS In healthy subjects, NET inhibition prevents tilt-induced neurally mediated (pre)syncope.
Therefore, NET inhibition may be a worthwhile target of drug intervention for larger trials
in highly symptomatic patients with neurally mediated syncope. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.07348:516–22) © 2006 by the American College of Cardiology Foundation
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(reatment of neurally mediated syncope is unsatisfactory.
atients with rare syncopal episodes may respond to reas-
urance, increased fluid and sodium intake, and physical
ountermeasures (1). Highly symptomatic patients would
ualify for more aggressive treatment. Numerous drugs have
een proposed for this indication. Given the questionable
fficacy, current guidelines do not recommend a particular
rug for the use in neurally mediated syncope (1). Further-
ore, recent trials showed that pacemaker therapy in
atients with neurally mediated syncope are of no value
2,3). This state of affairs may be explained by the fact that
he underlying pathophysiology of neurally mediated syn-
ope is still obscure (4). The “ventricular theory” proposed
hat activation of ventricular stretch receptors through
orceful contractions of an “empty” ventricle triggers brady-
ardia and vasodilatation (5). However, the left ventricle is
ot empty during syncope onset (6), and neurally mediated
yncope can occur in cardiac transplant patients with a
enervated heart (7). Furthermore, careful physiological
tudies in animals question the existence of ventricular
eceptors that respond to physiological changes in stretch
8,9). Excessive cardiac sympathetic activation was also
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ervice, Vanderbilt University, Nashville, Tennessee. This work was supported, in
art, by a Deutsche Forschungsgemeinschaft grant. Dr. Jordan received lecture fees
rom Abbott Pharmaceuticals.u
Manuscript received January 25, 2006; revised manuscript received March 10,
006, accepted April 10, 2006.mplicated earlier, giving rise to the widespread use of
eta-blockers. However, a number of studies failed to show
fficacy of beta-blockers in neurally mediated syncope (10–
4). In contrast, yohimbine-induced sympathetic activation
mproved, rather than worsened, orthostatic tolerance in
ighly selected syncope patients (15). Perhaps cardiac sym-
athetic activation is beneficial in neurally mediated syn-
ope. Inhibition of the neuronal norepinephrine transporter
NET) results in a more selective increase in cardiac
ympathetic drive (16). In a small number of healthy
ubjects, pharmacological NET inhibition delayed the onset
f head-up tilt-induced pre-syncope (17). We combined
ata sets from our current and earlier studies to confirm and
o extend the observation in a larger number of subjects.
ETHODS
tudy population. We studied healthy volunteers without
history of spontaneous syncope. Table 1 summarizes the
tudy population of the 3 substudies. The combined data set
omprised 51 individuals.
tudy design. All studies were conducted in a double-
lind, placebo-controlled, cross-over fashion. Subjects were
ested twice, once with placebo, and once with a NET
nhibitor. Treatment sequence was randomized. The dura-
ion of NET inhibitor treatment, the NET inhibitor used,
nd the head-up tilt protocol differed between studies
Table 1). Reboxetine is a selective inhibitor of NET that is
sed for treatment of depression (18,19). In the first study,
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August 1, 2006:516–22 Norepinephrine Transporter and Syncopeubjects ingested 8 mg reboxetine or matching placebo 13
nd 1 h before testing (17). In the second study, a single
ose of 8 mg reboxetine or placebo was given 90 min before
he tilt test. In the third study, subjects were treated with the
orepinephrine and serotonin transporter inhibitor sibutra-
ine (20). The drug is widely used for the treatment of obesity.
ubjects took 10 mg sibutramine 26 and 14 h, and 20 mg
ibutramine 2 h before testing or a matching placebo (21).
All head-up tilt studies were conducted after an overnight
ast and a baseline period of at least 30 min in the supine
osition. In studies 1 and 3, we conducted a graded head-up
ilt test. Subjects were subjected to 3 min each at 15°, 30°,
5°, and 60° head-up tilt, before the final tilt angle of 75°
as achieved. Subjects remained at 75° head-up tilt for 30
in. Maximal tilt time in studies 1 and 3 was 42 min
17,21). In study 2, subjects underwent a 45° head-up tilt for
aximal 30 min. Tilt testing was aborted prematurely by
he experimenters (C.S. and A.L.B.) when the subjects
eported intolerable orthostatic symptoms such as dizziness,
ausea, or visual disturbances. Neurally mediated (pre)syn-
ope was defined as either combined (vasovagal) type
progressive decrease in blood pressure and heart rate [HR]
f at least 30 mm Hg and 20 beats/min, respectively) or
asodepressor type (isolated progressive decrease in blood
ressure of at least 20 mm Hg). In all studies, blood pressure
as continuously monitored by a finger servoplethysmoma-
ometer (2300 Finapres, Ohmeda, GE Healthcare, Wauke-
ha, Wisconsin) that was kept at heart level throughout the
xperiments. In addition, blood pressure was measured by
n automated oscillometric sphygmanometer (Dinamap,
ritikon, GE Healthcare) at regular intervals. Heart rate
as monitored continuously by electrocardiogram (Viridia
MS, Hewlett Packard, Palo Alto, California).
atecholamine determinations. Plasma catecholamine
oncentrations were determined by a modified high-
ressure liquid chromatographic method (22) from blood
amples drawn after 30 min of supine rest and at the end of
ead-up tilting.
Abbreviations and Acronyms
DHPG  dihydroxyphenylglycol
HR  heart rate
NET  norepinephrine reuptake transporter
able 1. Study and Subject Characteristics
Study
No. Tilt Protocol Study Drug
1 3 min each at 15°, 30°, 45°, and 60°,
followed by 30 min at 75° head-
up tilt
Reboxetine 8 m
2 30 min at 45° head-up tilt Reboxetine 8 m
3 3 min each at 15°, 30°, 45°, and 60°,
followed by 30 min at 75° head-
up tilt
Sibutramine 10
2MI  body mass index.tatistics. The primary outcome variable was the tolerated
ilt duration in minutes with placebo and with NET
nhibition in the combined data set. The null hypothesis was
hat the tilt test duration with placebo and with NET
nhibition is equal. We compared variances between the
roups by using the F test. Student paired t test or Wilcoxon
atched pairs test was used to compare parametric and
on-parametric data, respectively. The odds ratio was cal-
ulated using a 2-by-2 table. Two-way analysis of variance
as used to test for sequence and treatment effects and
ossible interactions. Kaplan-Meier curves were compared
sing the log-rank test. All statistical tests were 2-tailed. A
alue for p  0.05 was considered significant. All data are
xpressed as mean  SEM.
ESULTS
f the 51 subjects, 27 received placebo on the first study
ay, followed by NET inhibition on the second day. The
emaining 24 subjects received study drugs in the reversed
rder. The mean tolerated tilt test duration was 29  2 min
ith placebo and 35  1 min with NET inhibition (p 
.001). We did not find an effect of treatment sequence on
olerated tilt test duration (p  0.5 for the interaction of
equence and treatment response). The odds ratio for
remature abortion of head-up tilt testing was 0.22 (95%
onfidence interval: 0.09 to 0.55, p  0.001) in favor of
ET inhibition compared with placebo. Figure 1 shows
Dosage n (M/F) Age (Yrs) BMI (kg/m2)
and 1 h before testing 24 (12/12) 29  1 23  1
min before testing 16 (16/0) 26  1 24  1
6 and 14 h and 20 mg
fore testing
11 (7/4) 27  2 23  1
igure 1. Individual differences in tolerated time during head-up tilt
esting between norepinephrine reuptake transporter (NET) inhibition and
lacebo treatment. In subjects who tolerated the full duration of the tilt
tudy, both on placebo and during NET inhibition, the difference is 0. The
olid vertical lines indicate the mean value and the boundaries of the 95%
onfidence interval.g 13
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Norepinephrine Transporter and Syncope August 1, 2006:516–22ndividual differences in tolerated head-up tilt duration
etween placebo and NET inhibition with reboxetine or
ibutramine. The improvement in tolerated tilt test duration
as consistent between studies (p  0.9 for the interaction
etween study and treatment response). The average im-
rovement in tolerated tilt test time was 6  3 min in study
(p  0.05), 6  2 min in study 2 (p  0.05), and 4  3
in in study 3 (p  0.11). With placebo, 26 subjects (51%)
ompleted tilt testing without symptoms. Twenty-five sub-
ects (49%) experienced (pre)syncope either of the combined
ype (n  23) or the vasodepressive type (n  2) during
ead-up tilt testing on the placebo day. With pharmacologic
ET inhibition, 42 subjects (82%) completed the test
ithout symptoms. In 9 subjects (18%), tilt testing was
borted prematurely, due to (pre)syncope of the combined
ype (n  2) or intolerable orthostatic symptoms without
radycardia or hypotension (n  7).
Of the 25 individuals who developed (pre)syncope during
ead-up tilt testing on the placebo day, 16 completed the
ilt test with NET inhibition without symptoms. All sub-
ects who experienced pre-syncope on both study days
ithstood the orthostatic stress for a longer time after NET
nhibition than with placebo (mean increase in orthostatic
olerance with NET inhibition 9  3 min compared with
hat of placebo). Three subjects developed pre-syncope
uring head-up tilt only with NET inhibition and had no
ymptoms on the placebo day. Figure 2 shows Kaplan-
eier plots for “tilt-test survival” for all 3 studies. “Tilt-test
urvival” was significantly improved with NET inhibition in
tudies 1 and 2 and borderline in significance for study 3.
Blood pressure and HR responses in the supine position
nd with head-up tilt are given in Table 2. In each study,
ET inhibition raised supine blood pressure and supine
R. In the combined data set, blood pressure was 117 
/66 1 mm Hg with placebo and 128 2/69 1 mm Hg
ith NET inhibition (p 0.0001 for systolic and0.01 for
iastolic blood pressure). Supine HR was 62  1 beats/min
ith placebo and 67  1 beats/min with NET inhibition
p  0.0001). In patients who completed head-up tilt
esting without pre-syncope, HR towards the end of tilt
esting was profoundly increased with NET inhibition
112  3 beats/min with NET inhibition, 87 3 beats/min
ith placebo, p  0.0001). Individual HR and blood
ressure data at the end of head-up tilt testing in (pre)syn-
opal patients are illustrated in Figure 3. These measure-
ents correspond to the last 10 s before the test had to be
borted. Both blood pressure and HR at the end of head-up
ilt were significantly higher in NET inhibition subjects
ompared with those of placebo-treated subjects. Figure 4
hows representative blood pressure and HR tracings over
he entire head-up tilt test in 1 subject with placebo and
ith NET inhibition.
Plasma concentrations of catecholamines are given in
able 3. Compared with placebo, NET inhibition de-
reased concentrations of norepinephrine and its main
egradation product, dihydroxyphenylglycol (DHPG), in phe supine position. During head-up tilt, DHPG concen-
rations were markedly reduced with NET inhibition, while
orepinephrine concentrations tended to be increased (p 
.07). The catecholamine profile in the supine position did
ot differ between (pre)syncopal subjects and subjects who
ompleted head-up tilt testing. With placebo, epinephrine
oncentrations in the upright position were 2-fold higher in
pre)syncopal subjects (115  20 pg/ml) compared with
ndividuals who completed head-up tilting without symp-
oms (63  7 pg/ml, p  0.01). With NET inhibition,
here was no difference in upright epinephrine concentra-
ions in (pre)syncopal and asymptomatic subjects (63  15
g/ml vs. 55  5 pg/ml, respectively, p  0.5).
ISCUSSION
e tested the hypothesis that short-term NET inhibition
igure 2. Kaplan-Meier plots for “tilt-test survival” with placebo (broken
ines) and norepinephrine reuptake transporter (NET) inhibition (solid
ines) for all 3 studies separately.revents head-up tilt-induced neurally mediated pre-
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August 1, 2006:516–22 Norepinephrine Transporter and Syncopeyncope or syncope. To address the issue in a sensitive
ashion, we combined the data set from 3 separate double-
lind, randomized, placebo-controlled studies in healthy
ubjects. Two of these studies have been previously pub-
ished (17,21). Norepinephrine reuptake transporter inhibi-
ion was remarkably effective in delaying or preventing
eurally mediated pre-syncope or syncope. Even in subjects
igure 3. Individual data of blood pressure and heart rate in (pre)syncopal
atients on norepinephrine reuptake transporter (NET) inhibition and on
lacebo immediately before tilt testing had to be aborted. bpm 
eats/min.ho experienced (pre)syncope, blood pressure and HR were iigher during NET inhibition compared with those seen
ith placebo. Our findings may have important pathophys-
ological and clinical implications.
In contrast with selective NET inhibition with rebox-
tine, sibutramine attenuates both neuronal norepinephrine
nd serotonin uptake (23). Thus, sibutramine could influ-
nce sympathetic regulation through changes in norepi-
ephrine turnover, changes in serotonin turnover, or both
echanisms combined. Whether serotonin is involved in
he pathophysiology of neurally mediated syncope is still
nder debate (4,9). Paroxetine, a serotonin reuptake
locker, has been shown to be effective in treating neurally
ediated syncope in a single study (24). However, in
nesthetized rabbits, selective inhibition of neuronal sero-
onin uptake had no effect on HR, arterial pressure, post-
anglionic renal sympathetic nerve activity, and norepi-
ephrine spillover (25). Thus, changes in autonomic
ardiovascular regulation with sibutramine in our study are
robably related to changes in norepinephrine uptake rather
han an effect on serotonin turnover.
Norepinephrine reuptake transporter has a central role in
orepinephrine turnover. Throughout the body, approxi-
ately 80% of released norepinephrine is taken up from the
ynaptic cleft through NET and either repackaged or
etabolized (26). Systemic NET inhibition is associated
ith complex changes in the regulation of the sympathetic
ervous system. In peripheral tissues, NET inhibition tends
o raise synaptic norepinephrine concentrations (16). In the
rain, NET inhibition has a sympatholytic effect presum-
bly through activation of alpha-2 adrenoreceptors
16,27,28). The balance between peripheral sympathetic
timulation and central sympathetic inhibition differs be-
ween organs. For example, in the kidney and in the
orearm, NET inhibition attenuates norepinephrine spill-
ver (16). In contrast, NET inhibition substantially in-
reases cardiac norepinephrine spillover (16). In the heart,
re- and post-synaptic membranes are located particularly
lose to each other (26). The anatomical feature makes the
eart more dependent on NET for removal of norepineph-
ine from the synaptic cleft. Thus, a larger proportion of the
eleased norepinephrine is taken up through NET in the
eart compared with other organs (29). Genetic NET
eficiency (30) and pharmacologic NET blockade (17)
nduce an increase in HR, particularly with standing.
ndeed, NET deficiency is a rare cause of the postural
achycardia syndrome. Thus, NET inhibitors are particu-
arly suitable to selectively increase adrenergic drive to the
eart.
The orthostatic tachycardia with NET inhibition is medi-
ted through beta-adrenoreceptor stimulation (21). The in-
reased upright HR with NET inhibition in our study is
onsistent with increased cardiac beta-adrenoreceptor stim-
lation. If neurally mediated syncope was mediated through
xcessive cardiac sympathetic stimulation, one would expect
o observe worsening in orthostatic tolerance with NET
nhibition. We found the opposite. Similarly, systemic
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Norepinephrine Transporter and Syncope August 1, 2006:516–22ympathetic activation with yohimbine improved orthostatic
olerance in highly selected patients with neurally mediated
yncope (15). All these findings challenge the concept that
xcessive adrenergic stimulation of the heart sets off
eurally mediated syncope. Therefore, it is not surprising
hat beta-blockers are not efficacious in syncope treat-
ent (10 –14).
During neurally mediated syncope, sympathetic activity
ecreases suddenly resulting in vasodilatation and bradycar-
ia (5). It has been suggested that epinephrine released
efore the onset of the hypotension may trigger neurally
ediated syncope (31). Similar to previous studies (5,31–
3), epinephrine concentrations in the upright position were
arkedly increased in (pre)syncopal subjects on placebo.
orepinephrine reuptake transporter inhibition “normal-
able 2. Systemic Hemodynamics in the Supine and Upright Po
Study
No. Treatment
Supine
SBP
(mm Hg)
DBP
(mm Hg)
HR
(beats/
1 Placebo 118  2 69  1 64 
NET inhibition 128  8* 72  2† 68 
2 Placebo 120  3 65  2 61 
NET inhibition 133  3* 68  1 69 
3 Placebo 112  3 61  1 58 
NET inhibition 121  3* 65  2 62 
All Placebo 117  2 66  1 62 
NET inhibition 128  2* 69  1‡ 67 
p  0.001, †p  0.05, ‡p  0.01.
DBP  diastolic blood pressure; HR  heart rate; NET  norepinephrine trans
igure 4. Original beat-by-beat tracings of finger blood pressure (BP) (up
n placebo (left) and on norepinephrine reuptake transporter (NET) inh
eurally mediated pre-syncope with a sudden decrease in HR and BP after 24 min
ncreased. The subject was able to complete the tilt protocol (42 min) withoutzed” upright epinephrine concentrations in these subjects.
t is possible that the beneficial effect of NET inhibition on
rthostatic tolerance is explained, in part, by attenuated
pinephrine release. Another possible explanation for the
eneficial effect of NET inhibition is that higher synaptic
orepinephrine concentrations are maintained even when
ympathetic efferent activity shuts off. Possibly, NET inhi-
ition interferes with the still unknown neural pathways
hat induce sympathetic withdrawal. Earlier pacemaker
tudies addressed the issue of bradycardia directly; however,
he results were disappointing (2). In an accompanying
ditorial to that study, the issue was raised if there is an
ffective treatment for neurally mediated syncope (34). Our
tudy cannot answer that question. Nevertheless, we believe
hat we have made a step in the right direction.
and Mean Tilt Duration
Upright
Mean Tilt
Duration (min)
SBP
(mm Hg)
DBP
(mm Hg)
HR
(beats/min)
122  4 79  4 86  6 30  2
116  5 76  2 119  4‡ 37  2†
120  6 72  2 84  6 22  3
117  6 72  2 106  7‡ 29  1†
107  3 70  3 92  4 38  3
113  3 74  3 106  4* 42  0
116  3 74  2 87  3 29  2
116  3 75  1 112  3* 35  1‡
; SBP  systolic blood pressure.
racings) and heart rate (HR) (lower tracings) in a representative subject
n with reboxetine (right). On placebo, the patient experienced a typicalsition
min)
2
2†
2
2‡
2
2‡
1
1*per t
ibitioof head-up tilt (asterisk). On NET inhibition, upright HR was markedly
pre-syncope. bpm  beats/min.
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August 1, 2006:516–22 Norepinephrine Transporter and SyncopeThe major limitation of our work is that we studied
false-positive” subjects without a history for spontaneous
yncope. The mechanism leading to bradycardia and hypo-
ension may differ between “false-positive” subjects and
yncope patients. Even between different subsets of syncope
atients, the mechanism may not be the same (35). For
xample, in a subset of older syncope patients with very
requent syncopal spells, sympathetic activity fails to in-
rease properly with upright posture resulting in a more
radual depressor response (5). In other patients, sympa-
hetic activity is not reduced until the actual onset of
yncope (36). Given the heterogeneity of sympathetic reg-
lation, our results may not be simply extrapolated to all
yncope patients. Yet the underlying neural mechanism
ppears to be similar in a larger proportion of syncope
atients and in “false-positive” control subjects. We deter-
ined the response to short-term NET inhibition. Thus,
e cannot exclude the possibility that the effect of NET
nhibition on neurally mediated syncope abates over time.
inally, the high occurrence of tilt-induced (pre)syncope in
ur study population of healthy volunteers is somewhat
urprising. In fact, the percentage of false-positive results of
ead-up tilt testing in healthy controls varies extremely.
his heterogeneity may be explained, in part, with differ-
nces in tilt testing protocols (37,38). One possible expla-
ation for the large number of false-positive tilt tests in our
tudy is the instrumentation with intravenous catheters.
Despite these issues, we suggest that NET may be
nvolved in the pathogenesis of neurally mediated syncope.
orepinephrine reuptake transporter inhibition may be a
orthwhile target of drug intervention for larger trials in
ighly symptomatic patients with neurally mediated syn-
ope. However, given the benign prognosis of the condition,
potentially beneficial effect has to be weighed against a
ignificant increase in blood pressure and HR.
eprint requests and correspondence: Dr. Jens Jordan, Franz-
olhard Clinical Research Center, Charité Campus Buch, Wilt-
ergstr. 50, Haus 129, 13125 Berlin, Germany. E-mail: jordan@
vk.charite-buch.de.
able 3. Supine and Upright Catecholamines With Placebo and
ith NET Inhibition
Placebo p Value NET Inhibition
upine NE (pg/ml) 226  14 0.011 191  10
pinephrine (pg/ml) 20  3 0.2 23  3
HPG (pg/ml) 857  45 0.0001 572  21
HPG/NE 4.2  0.3 0.012 3.5  0.2
pright NE (pg/ml) 484  30* 0.066 547  25*
pinephrine (pg/ml) 83  10* 0.011 57  5*
HPG (pg/ml) 1,061  48* 0.0001 672  25*
HPG/NE 2.6  0.2* 0.0001 1.3  0.1*
p  0.001 supine vs. upright.
DHPG dihydroxyphenylglycol; NE norepinephrine; NET norepinephrine
ransporter.EFERENCES
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